Patent · US Active

Cancer neoepitopes

US11421016B2 · kind B2 · utility

4Cited by
3References
17Claims
0Family size

Assignees

Inventors

Key dates

Filing dateApr 25, 2016
Grant dateAug 23, 2022
Priority date
Expiry dateNov 16, 2038

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12Q2600/158
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Contemplated compositions and methods are directed to cancer neoepitopes and uses of such neoepitopes, especially to generate synthetic antibodies against neoepitopes that may then be employed in the manufacture of a therapeutic agent. Preferred therapeutic agents will comprise a synthetic antibody against a neoepitope, and most preferably in combination with a cellular or non-cellular component for use as a diagnostic or therapeutic agent.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.